Eli LillyLLY
Market Cap: $858B
About: Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Employees: 43,000
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
38% more first-time investments, than exits
New positions opened: 263 | Existing positions closed: 190
20% more funds holding in top 10
Funds holding in top 10: 447 [Q1] → 535 (+88) [Q2]
16% more capital invested
Capital invested by funds: $608B [Q1] → $706B (+$98.1B) [Q2]
14% more repeat investments, than reductions
Existing positions increased: 1,475 | Existing positions reduced: 1,292
11.1% more ownership
Funds ownership: 70.99% [Q1] → 82.1% (+11.1%) [Q2]
2% more funds holding
Funds holding: 3,371 [Q1] → 3,444 (+73) [Q2]
18% less call options, than puts
Call options by funds: $8.06B | Put options by funds: $9.87B
Research analyst outlook
29 Wall Street Analysts provided 1 year price targets over the past 3 months
29 analyst ratings
Morgan Stanley Terence Flynn 75% 1-year accuracy 15 / 20 met price target | 23%upside $1,106 | Overweight Reiterated | 27 Aug 2024 |
Cantor Fitzgerald Louise Chen 70% 1-year accuracy 112 / 159 met price target | 2%downside $885 | Overweight Reiterated | 19 Aug 2024 |
Guggenheim Seamus Fernandez 67% 1-year accuracy 4 / 6 met price target | 14%upside $1,030 | Buy Maintained | 16 Aug 2024 |
Berenberg Kerry Holford 100% 1-year accuracy 2 / 2 met price target | 16%upside $1,050 | Buy Maintained | 14 Aug 2024 |
Deutsche Bank James Shin 100% 1-year accuracy 5 / 5 met price target | 14%upside $1,025 | Buy Upgraded | 12 Aug 2024 |
Financial journalist opinion
Based on 172 articles about LLY published over the past 30 days